CLEAR Outcomes Company Update Call: Detailed Results Discussion

Rhea-AI Summary

Esperion (NASDAQ: ESPR) will host a conference call on March 6, 2023, at 8:00 a.m. EST to discuss the results from the CLEAR Outcomes study, being presented at the ACC.23/WCC on March 4, 2023. Dr. JoAnne Foody, Chief Medical Officer, and Dr. Steven Nissen, Principal Investigator, will lead the discussion. Participants can pre-register for the call and obtain dial-in information through the provided link. The call will also be available as a replay on the company's investor relations website for 90 days following the event. Esperion focuses on developing innovative treatments for cardiovascular diseases, particularly high cholesterol management.

Positive

• Scheduled discussion of CLEAR Outcomes study results is expected to share significant insights into cardiovascular treatments.
• Participation from notable experts adds credibility to the conference, enhancing investor confidence.

Negative

• None.

ANN ARBOR, Mich., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a conference call and webcast on Monday, March 6^th, 2023 where Esperion Chief Medical Officer Dr. JoAnne Foody and CLEAR Outcomes Principal Investigator Dr. Steven Nissen will discuss detailed results from CLEAR Outcomes, which are being presented at the American College of Cardiology Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC) on Saturday, March 4^th, 2023.

The webcast and conference call will take place at 8:00 a.m. EST / 7:00 a.m. CST on March 6^th, 2023. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.

Already registered? Access with your PIN here.

A webcast of the live call will be available online in the investor relations section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company’s website for approximately 90 days.

Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.

Contact:
Esperion Corporate Communications
corporateteam@esperion.com

FAQ

What is the date of the Esperion conference call regarding CLEAR Outcomes results?

The Esperion conference call will take place on March 6, 2023.

Who will be presenting the CLEAR Outcomes results during the conference call?

Dr. JoAnne Foody, Chief Medical Officer, and Dr. Steven Nissen, Principal Investigator, will present the results.

Where can I access the webcast of the Esperion conference call?

The webcast can be accessed on Esperion's investor relations website.

What is the focus of Esperion's innovative medicines?

Esperion focuses on improving outcomes for patients with cardiovascular and cardiometabolic diseases, especially high cholesterol.

When will the CLEAR Outcomes results be presented at ACC.23/WCC?

The results will be presented on March 4, 2023.